Novartis to buy BMS OTC brands for $660 million

Share this article:
Novartis is buying the U.S. and Canadian OTC business of Bristol-Myers Squibb for $660 million, giving the Swiss firm entry into the $2 billion U.S. market for adult tablet headache remedies with Excedrin.
The deal includes rights to market the brands in Latin America, the Middle East, Europe and Africa, where net sales totaled $16 million in 2004. Sales of the drugs in the U.S. and Canada were $242 million in 2004. Also included are limited rights to Moisturel and Lac-Hydrin in Canada, along with several dormant trademarks. BMS is holding on to its local and regional consumer medicines business, which is run separately. Manufacturing facilities were not included. 
In addition to Excedrin, which had U.S. sales of $160 million in 2004, the business includes Keri skin care, decongestant 4-Way, cold and flu treatment Comtrex, No-Doz, antifungal Vagistat and analgesics Bufferin and Mineral Ice. Novartis' existing OTC business includes ExLax, Maalox, Theraflu and Lamisil AT.
BMS announced in January that it was divesting the unit as part of its effort to refocus its business on specialty pharmaceuticals.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...